Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

A Texas federal jury has found that Daiichi Sankyo’s breast cancer blockbuster Enhertu infringes a patent held by Seagen and has awarded $41.8 million in royalty revenue from the China-based company.